NOV 13, 2018 7:46 AM PST

Clinical Trial Drug For a Rare Neurodegenrative Disease Proven Unsuccessful

WRITTEN BY: Nouran Amin

Niemann-Pick type C (NPC) is a rare and fatal neurodegenerative disease. Symptoms of the condition include loss of balance, difficulty swallowing, seizures, and cognitive disabilities. These symptoms are due to an impaired ability to properly metabolize cholesterol.

Seeking treatment for NPC, a recent drug was placed in a key clinical trial for 56 affected children and youth. The drug, VTS-270, brought disappointing results when it was found to perform no differently than the placebo and “did not show a statistically significant separation,” says Steven Romano, the executive vice president of Mallinckrodt Pharmaceutical and chief scientific officer. However, the condition did not progress in both groups during the 1-year study.

“But importantly, neither did [patients in the active or placebo arms of the trial] show disease progression as would have been anticipated in the neurodegenerative condition over 52 weeks of observation,” explains Romano.

VTS-270 consists of a doughnut-shaped sugar molecule called a cyclodextrin that was spinally injected into the cerebrospinal fluid of the brain.

The chemical structure of VT2-270 (2-hydroxypropyl-β-cyclodextrin (HPβCD))

Image Credit: PLOS ONE

The drug showed positive results in animal models of the diseases but not in children during the one year study. Such results prompted other researchers who have expertise in rare diseases to suggest that the trial’s use of a traditional double-blind and randomized controlled trials may not be the best tool in such condition.

“This is a disappointing result but a very important one. The question I have is: Is it truly the case that this agent is not effective, or is the result the consequence of a trial design that in retrospect might have been better?” says Marc Patterson, a child neurologist who has been conducting NPC research and treating NPC-affected children for over 30 years.

Since NPC is a slow progressive disease, Patterson believe that the drug may have been successful if the clinical trial was much longer than the 1-year study. Patterson argues that this particular study raises issues regarding FDA’s approval time in clinical trials involving rare diseases.

“We’ll need to look at those open-label treatment patients and see if there’s any difference that gradually accrues over the course of that additional treatment period,” says Romano.

Source: Science Magazine

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
MAR 21, 2021
Microbiology
Potent Drug Rapidly Clears Drug-Resistant Gonorrhea in Mouse Model
MAR 21, 2021
Potent Drug Rapidly Clears Drug-Resistant Gonorrhea in Mouse Model
A mouse model has shown that it's possible to clear a multi-drug resistant gonorrhea with only one dose of antibioti ...
MAR 30, 2021
Cardiology
Looking at a Fertility Drug's Cardiac Safety
MAR 30, 2021
Looking at a Fertility Drug's Cardiac Safety
New drugs go through a long and arduous process before they can grace a doctor’s office. One of the last steps is ...
APR 01, 2021
Immunology
Tumor-Killing 101: Vaccine Trains Immune Cells to Keep Skin Cancer at Bay
APR 01, 2021
Tumor-Killing 101: Vaccine Trains Immune Cells to Keep Skin Cancer at Bay
Cancer researchers have developed a therapeutic vaccine for melanoma, a deadly form of skin cancer. Instead of protectin ...
MAY 14, 2021
Health & Medicine
A National Standard THC Dose for Researchers is Here
MAY 14, 2021
A National Standard THC Dose for Researchers is Here
    Whatever your stance on cannabis, almost  everyone would agree that more, better quality, research sh ...
MAY 25, 2021
Cell & Molecular Biology
A simplified high-throughput protein expression system
MAY 25, 2021
A simplified high-throughput protein expression system
Protein synthesis, protein engineering, and synthetic biology researchers can research their protein of interest using e ...
JUN 09, 2021
Drug Discovery & Development
New Drug Prevents Dementia After Head Injury
JUN 09, 2021
New Drug Prevents Dementia After Head Injury
Researchers led by the University of South Australia have identified a new drug that may be able to help prevent athlete ...
Loading Comments...